The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
Advancing to IND-enabling studies with multiple drug candidates
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Subscribe To Our Newsletter & Stay Updated
